Opinion|Videos|February 28, 2025
Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches
Panelists discuss studies aimed at combating dose-dependent anemia as a consequence of Janus kinase inhibitors (JAKi) treatment and share their thoughts on potential strategies to address this challenge.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Dr Kuykendall to faculty: Dose-dependent anemia can be a consequence of treatment with JAKi. What are your thoughts on studies aimed at combating this challenge?
Advertisement
Related to this article
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5